Qingruike^® Pregabalin Oral Solution contains pregabalin, a calcium channel modulator that targets the α2-δ subunit of voltage-gated calcium channels. Besides relieving pain, it also improves sleep and mood. Clinically, it is mainly used for postherpetic neuralgia, fibromyalgia, and as adjunctive therapy for partial-onset seizures in adults, making it a preferred choice in relevant guidelines. Additionally, it is recommended in other literature and guidelines for conditions such as migraine, postoperative pain, refractory neck pain, burn pain, phantom limb pain, and restless legs syndrome.

Qingruike^® Pregabalin Oral Solution was launched in November 2022 and included in the national medical insurance negotiation list in 2023. As an oral solution formulation distinct from traditional solid tablets in China, Qingruike® offers faster absorption and more precise and flexible dosing, meeting a broader range of patient needs without compromising pregabalin’s established therapeutic benefits.